A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme

Neurology

Volumn 58, Issue 12, 2002, Pages 1759-1764

  Brandes, A A ^a   Turazzi, S ^b   Basso, U ^a   Pasetto, L M ^a   Guglielmi, B ^c   Volpin, L ^c   Iuzzolino, P ^b   Amista P ^a   Pinna, G ^b   Scienza, R ^a   Ermani, M ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Azienda Ospedale Universita   (Italy)

^c Department of Pathology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CARMUSTINE; NITROSOUREA DERIVATIVE; PROCARBAZINE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SKIN ALLERGY; THROMBOCYTOPENIA;

EID: 0037172832     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.12.1759     Document Type: Article

References (27)

1. Brain tumor survival: Results from the National Cancer Data Base
2. High dose chemotherapy with bone marrow rescue for high grade gliomas in adults
3. New drugs in recurrent high grade gliomas
4. 6-benzylguanine for patients with recurrent or progressive malignant glioma
5. The role of chemotherapy in recurrent malignant gliomas: An overview
6. The basis for current treatment recommendations for malignant gliomas
7. 6-alkyl guanine alkyltransferase (AGT) in cancer chemotherapy
8. DNA-crosslinking and monoadduct repair in nitrosourea-treated human tumor cells
9. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas
10. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
11. 6-alkylguanine-DNA alkyltransferase
12. 6-alkylguanine-DNA alkyltransferase by alkylating agents or alkylated DNA
13. 6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine
14. Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high grade gliomas
15. Increased pulmonary toxicity with scheduling procarbazine prior to BCNU in patients with high-grade gliomas
16. Malignant astrocytic neoplasms: Classification, pathology, anatomy and response to treatment
17. WHO handbook for reporting results of cancer treatment (WHO offset publications no. 48)
18. Response criteria for phase II studies of supratentorial malignant glioma
19. Optimal two-stage designs for phase II clinical trials
20. Nonparametric estimation for incomplete observation
21. Regression models and life tables
22. Outcomes and prognostic factors in recurrent glioma patients enrolled into phase II clinical trials
23. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse
24. Response to carmustine, tumor control, and survival in recurrent glioblastoma multiforme
25. Modified procarbazine CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors
26. PCV chemotherapy useful in the treatment of recurrent glioblastoma multiforme?
27. Determinants of time to progression and overall survival of patients in clinical trials for recurrent glioma